CMR Surgical announces more than 100 Versius systems installed globally
CMR Surgical announces more than 100 Versius systems installed globally CMR is delivering on its commercial strategy of rapid global...
Cancer
Immatics Announces Third Quarter 2022 Financial Results and Business Update
Interim clinical update on ACTengine® IMA203 TCR-T monotherapy targeting PRAME demonstrated high confirmed objective response rate (cORR) of 50% (6/12)...
CytomX and Regeneron Announce Strategic Research Collaboration in the Field of Conditional Bispecific Therapeutics for the Treatment of Cancer
- Collaboration will enable the development of investigational next-generation bispecific immunotherapies using CytomX’s Probody® and Regeneron's Veloci-Bi® platforms - -...
MUHC’s Got Talent raises $677,000 in fundraiser where health care workers take to the stage
MUHC’s Got Talent saw Quebecers vote for their favourite performances by MUHC health care staff, crowning five winners in support...
Evaxion announces promising results from Phase 1/2a clinical trial of personalized DNA cancer immunotherapy EVX-02
COPENHAGEN, Denmark, Nov. 17, 2022 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology...
CMR Surgical announces more than 100 Versius systems installed globally
CMR Surgical announces more than 100 Versius systems installed globally CMR is delivering on its commercial strategy of rapid global...
ExCellThera announces completion of Phase 2 clinical trials for UM171-expanded cell therapy in high-risk blood cancers
MONTREAL, Nov. 15, 2022 (GLOBE NEWSWIRE) -- ExCellThera Inc. (ExCellThera), a world leader in blood stem cell expansion and rejuvenation,...
Todos Medical Announces Third Quarter 2022 Financial Results
§ 89% increase in Q3/2022 quarterly revenues as compared with Q3/2021 § Earnings and business update call to be held at 8:30am...
Apexigen Reports Third Quarter 2022 Financial Results and Provides Business Update
-Ongoing Phase 2 trial in collaboration with Columbia University demonstrated that sotigalimab (sotiga) in combination with doxorubicin achieved a median...
Rakovina Therapeutics Announces Publication Highlighting Activity of Novel Bi-functional PARP-HDAC Inhibitor in Preclinical Models of Ewing Sarcoma
Publication to be available on pre-print server, bioRxiv, and will be submitted for scientific journal peer-review VANCOUVER, British Columbia, Nov....
INmune Bio, Inc. Receives Health Canada “No Objection Letter” to Commence Clinical Trial of XPro1595 in Mild Alzheimer’s Disease
BOCA RATON, FL., Nov. 14, 2022 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on...
Biofrontera Inc. Reports Third Quarter 2022 Financial Results and Provides a Business Update
Conference call begins at 11:00 a.m. Eastern time today WOBURN, Mass., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq:...
Agenus Data at SITC 2022 Highlight Durable Responses of Botensilimab / Balstilimab Combination in Nine Different Treatment-Resistant Cancers
Overall response rates ranged from 22% in microsatellite stable colorectal cancer (MSS-CRC) to 60% in PD-(L)1 refractory non-small cell lung...
James Rosenbaum Presented the Distinguished Service Award by the American College of Rheumatology
BURLINGAME, Calif., Nov. 14, 2022 (GLOBE NEWSWIRE) -- James T. Rosenbaum, MD, Senior Vice President of Research at Corvus Pharmaceuticals...
Vaccinex Reports Third Quarter 2022 Results and Provides Corporate Update
Continued Progress in Pepinemab Oncology and Neurology Clinical ProgramsPromising initial responses in Phase 1b/2 open-label KEYNOTE B84 study of pepinemab...
Adial Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update
Advancing submission of AD04 ONWARD™ phase 3 results to regulatory agencies Actively exploring potential partnership opportunities for AD04 and Purnovate...
Cue Biopharma Announces $30 Million Private Investment in Public Equity (PIPE) Financing
BOSTON, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of...
SELLAS Life Sciences Provides Business Update and Reports Third Quarter 2022 Financial Results
– Cash Position of $21.3 Million as of September 30, 2022 – – Hosting Phase 3 REGAL Study Update Webcast...
Immutep Receives Australian R&D Tax Incentive
Media Release (Code: ASX: IMM; NASDAQ: IMMP) SYDNEY, AUSTRALIA, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ:...
Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2022 and Provides Business Update
NORCROSS, Ga., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target...